- American City Business Journals•31 minutes ago
Philadelphia gene therapy company Spark Therapeutics said it is in the final stages of completing its rolling biologics license application for its lead product: a one-time treatment for an inherited retinal disease that causes blindness in children. The application for voretigene neparvovec— which is being submitted in parts to the Food and Drug Administration— is expected be done in early 2017, pending the finalization of the remaining release and stability testing, the company said. “We look forward to continued innovation, execution and growth in 2017, which may be a historic year for Spark Therapeutics and for patients as we potentially deliver what has been unimaginable before – the first gene therapy in the United States for a genetic disease,” said Jeffrey D. Marrazzo, the company’s co-founder and CEO.
- Investopedia•2 hours ago
Momenta’s 4Q earnings came in at a healthy 60 cents per share, or $41.5 million.
- Market Realist•4 hours ago
The Animal Health segment’s contribution increased to 8.7% of total revenues for 4Q16, compared to 8.1% for 4Q15.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.25 - 33.75|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.73|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|